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Abstract
Background: Little is known about regional variation in cancer treatment and its determinants. We compare rates
of adherence to treatment guidelines for elderly patients across Texas and whether local specialist supply is an
important determinant of treatment variation.
Methods: Previous literature reviewed indicated 7 recommended courses of treatment for colorectal, pancreatic,
and prostate cancer. We analyzed Texas Cancer Registry data linked with Medicare claims for the years 2004 to
2007 to study patients with these cancers. We tested for unadjusted and adjusted differences in treatment rates
across 22 hospital referral regions (HRR). We tested whether variation in the local supply of specialists treating each
cancer was an important determinant of treatment.
Results: We found significant differences in adjusted treatment rates across regions. For removal and examination
of 12+ lymph nodes with colon cancer resection, 13 of 22 HRRs had rates significantly different from the median
region. For adjuvant chemotherapy for regional colon cancer, five HRRs significantly differed from the median. For
prostate cancer treatment with a favorable diagnosis, nine HRRs differed from the median HRR. Of the 7 treatments,
only the local availability of surgeons was an important determinant for excision of lymph nodes for colon cancer
patients.
Conclusions: There are significant variations across Texas for seven recommended cancer treatments. No one
region has consistently higher or lower treatments than other regions, and local specialist supply is not an
important predictor of treatment. Different factors may be determining regional variation in treatment rates across
cancer types and treatment options.
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Background
Overall cancer mortality has declined in the U.S. over the
past several decades, and most site-specific cancers have
also experienced decreased mortality rates [1]. Advances
in screening and treatment have contributed to reduced
death rates from cancer over time. However, as medical
technology for treating cancer becomes more complex
and the options for treatment become more diverse, it also
becomes more challenging to guarantee that all patients
are receiving high quality treatment, given their diagnosis.
This study compares rates of high quality treatment
for patients aged 65+ across regions of Texas. Several
studies have identified regional variation in treatment
for individual cancer types [2–10]. Past studies compar-
ing risk adjusted Medicare spending across regions give
the impression that some areas tend to treat patients of
all types more aggressively than others [11–13]. However,
no study has simultaneously compared treatment rates for
multiple cancer therapies to determine whether certain
areas tend to treat patients at a higher or lower rate rela-
tive to other regions.
In addition, not all past studies have compared treat-
ment relative to recommended guidelines for care.
Physicians can obtain guidelines for cancer care from the
National Comprehensive Cancer Network Guidelines, the
American Society of Clinical Oncology Practice Guidelines,
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or from peer-reviewed manuscripts. Previous studies
have identified low rates of appropriate treatment in
the U.S. for a variety of cancer illnesses [1, 2, 14–17].
Factors that have been associated with variation in
guideline compliance include age, comorbidities, insur-
ance type, institution, and region [14, 17]. We compare
actual treatment to recommended guidelines for seven
treatments covering three site-specific cancers across
Texas.
Texas is a particularly useful state in which to exam-
ine regional variation, because it is so large and diverse
demographically and geographically. It is the second
most populous U.S. state, with 27 million people in
2014. An estimated 113,630 new cancer cases, or 7 % of
all U.S. occurrences are predicted for Texas for 2015
[18]. The state has several urban and rural areas and an
ethnically diverse population. Some regions have access
to large teaching hospitals, while many do not. We have
access to Texas Cancer Registry data linked to Medicare
claims files, which enables us to reliably determine cancer
stage at diagnosis and follow the course of treatment for
older patients over time and across multiple providers.
Some studies have found that the local supply of
physicians is a significant determinant of survival or
treatment rates for cancer [19–25]. Less research has
been conducted comparing the supply of specialists
who treat cancer patients to regional variations in
treatment, [6, 26] although one study found that the
local supply of medical specialists and acute care hos-
pital capacity explains 41 % of variation in end-of-life
health care spending across U.S. hospital referral re-
gions [11]. We test whether the supply of specialists
available to treat each cancer is a significant determin-
ant of treatment rates for the elderly.
Methods
Treatments
We chose to study treatments for cancers in which we
had prior research experience and were therefore most
familiar with recommended guidelines. Previous litera-
ture was reviewed to identify 7 recommended courses
of treatment for colorectal, pancreatic, and prostate
cancer that could be readily measured with claims data.
These recommended courses include 1) removal and
pathological examination of at least 12 lymph nodes
during resected colon cancer, 2) adjuvant chemotherapy
within 4 months of diagnosis for patients under age 80
with regional colon cancer, 3) radiation therapy within
6 months of diagnosis for patients under the age of 80
with regional spread of rectal cancer who received sur-
gical resection, and 4) postoperative adjuvant chemo-
therapy for patients under age 80 years with regional
rectal cancer [27]. Relatively low rates of adherence to
these recommended treatments have been documented
in the U.S. previously [28]. 5) Pancreatic resection is
recommended for patients with localized disease, or for
patients with regional pancreatic cancer that is not locally
advanced [29]. Low rates of pancreatic resection have also
been documented in the U.S. [15]. All of these treatments
were recommended courses of care during the study’s
sample period.
Appropriate treatment for men with non-metastatic
prostate cancer depends on disease characteristics; there-
fore, we distinguish between cancers with a “favorable”
versus an “unfavorable” prognosis. Patients with non-
metastatic prostate cancer can be treated with external
beam radiation therapy, brachytherapy, prostatectomy,
cryosurgery, androgen deprivation therapy [16]. How-
ever, there is no compelling data from published ran-
domized trials that men age 65 and older with relatively
low risk prostate cancer derive a survival or quality of
life benefit from cancer-directed treatment [30, 31]. In
fact, randomized trials demonstrate that in older men
with low-risk prostate cancer, observation yields similar
survival and decreased morbidity compared with up-
front treatment [31, 32]. Most men with a diagnosis of
low-risk prostate cancer in the United States received
up-front treatment with prostatectomy or radiotherapy
and are thus exposed to the risk of treatment-induced
urinary dysfunction, rectal bleeding, and impotence.
We define appropriate treatments for prostate cancer
as 6) receipt of cancer-directed treatment within one
year of diagnosis for those patients with an unfavorable
prognosis, and 7) no cancer-directed treatment within
one year (observation) for patients with a favorable
prognosis. Relatively high rates of cancer-directed treat-
ment have been documented for prostate cancer patients
with both favorable and unfavorable prognoses [16].
Data
We analyzed data from the Texas Cancer Registry-
Medicare linked database. Medicare provides health in-
surance for U.S. residents who are 65 or older. The
linkage was performed under the guidance of TCR, the
National Cancer Institute, and the Center for Medicare
and Medicaid Services. The data used in this study in-
cludes patients diagnosed with the study cancers between
2004 and 2007 and their Medicare claims through 2008.
Patients in the sample met the following criteria: diag-
nosed and reside in Texas, age 65 years or older, first diag-
nosed in 2004 to 2007 and not at time of death, first
primary cancer and no second primary cancer within
12 months, histology confirmation, continuously enrolled
in Medicare Parts A and B pre- and post-diagnosis, and
not a member of an HMO 12 months pre- and post-
diagnosis. Analysis was limited to appropriate subpopula-
tions when recommended courses of treatment designated
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specific cancer stages for care. Only men were included in
the analysis of prostate cancer treatment.
Patient-level variables evaluated included gender, age
at diagnosis, race/origin, Charlson comorbidity score
using a NCI defined algorithm, [33] tumor size, cancer
stage, and year of diagnosis. Age was categorized into
the intervals 65–70, 70–75, 76–80, and 81+. Analysis
for colon and rectal treatments was limited to patients
80 and under, based on treatment guidelines. We also
controlled for certain census tract-level indicators of
patient socioeconomic status. Median income in the
census tract of residence from the 2000 U.S. Census
was included in the TCR-Medicare linked database.
Median incomes were classified into quartiles ($ <31,000;
$31,000–< $39,000; $39,000–<$53,000; and $53,000+).
These variables included urban/rural location, percent of
individuals who do not speak English, percent of indi-
viduals who have completed at least some college, and
median income. We determined the hospital referral re-
gion (HRR) that each patient resided in. HRRs represent
regional health care markets for tertiary care [34]. The
U.S. is divided into 306 HRRs, and 22 are in Texas.
The TCR data and Medicare billing claims were used
to determine the treatments within the specific time
frame of cancer diagnosis; the methods to identify the
treatments have been previously described in the litera-
ture [16, 28, 29]. Patients were identified from the TCR
Patient Entitlement and Diagnosis Summary file using
major site groups that SEER has defined based on the
primary site and ICD-O-3 morphology. The TCR con-
tained the cancer disease stage at diagnosis for each
patient.
We also classified the prostate cancer patients as
favorable risk (stage T1 or T2 tumor and low histologic
grade) versus unfavorable risk (T3 or T4 tumor or
intermediate/ high histologic grade) [16]. PSA information
is not currently captured by TCR and so could not be
incorporated into patient risk stratification.
We counted the number of specialists per 1,000
Medicare elderly patients who had at least one Medicare
claim with an accompanying diagnosis of neoplasm (ICD9
diagnosis codes 140–239) in each Hospital Service Area
(HSA). HSAs are local health care markets for hospital
care. An HSA is a collection of ZIP codes whose resi-
dents receive most of their hospitalizations from the
hospitals in that area [34]. There are 3,436 HSAs in the
U.S. and 208 in Texas. The Dartmouth Atlas, which de-
fined HRRs and HSAs, aggregates the HSAs to define
HRRs. Specialist types were defined based on the treat-
ment guideline being examined. For example, for surgi-
cal removal of lymph nodes during colorectal resection,
we counted the number of surgeons per HSA. But for
radiation therapy for a diagnosis of regional rectal can-
cer, the number of radiation oncologists was counted.
Specialists associated with each cancer are listed in
Additional file 1: Table S1.
Statistical analysis
We first report the mean treatment rates for each cancer
type in our study across all patients in Texas. We then re-
port the treatment rate in the median HRR in the state for
each recommended course of care, as well as the lowest
and highest treatment rates by HRR. We list the name of
the HRR associated with each reported rate, so that we
can look for similarities and differences in cancer care
across regions in Texas.
In regression analyses for each treatment, the dependent
variable was set equal to 1 if the patient received the
recommended treatment given their diagnosis and 0
otherwise. We first estimated logistic regressions that
included only the HRRs as explanatory variables to test
for variation in appropriate treatment across parts of
Texas. For each treatment, we set the HRR with the
median treatment rate for the sample as the excluded
category in the regressions. We then tested for differ-
ences in treatment rates across HRRs, adjusting for pa-
tient characteristics, census tract-level characteristics,
and the supply of cancer specialists in the HSA. Cancer
stage (local, regional, or distant versus in situ) was in-
cluded in the colon cancer regression. For the other
treatments, cancer stage was used to define the cancdidate
treatment population and was therefore not a regressor.
We include the supply specialists when measuring the
determinants of favorable treatment for prostate cancer,
because we seek to test whether the overly high rate of
cancer-directed treatment for this patient group may be
an example of “supply-sensitive care.” This term refers to
clinical activities for which the frequency of use is related
to the capacity of the local healthcare system, but which
do not yield better health outcomes [11, 35]. All regres-
sion analyses were conducted using Stata 11.2, and stand-
ard errors were computed using the cluster option to
account for correlation in unobservables across HRRs
[36]. Means of all of the explanatory variables included in
the regressions are listed by treatment status in Additional
file 1: Table S2.
Results
Table 1 provides descriptive statistics on mean treatment
rates for the 7 recommended courses of cancer care, as
well as information on the Texas HRRs with median,
minimum, and maximum treatment rates. We report
the number of cancer patients eligible for each recom-
mended treatment in each HRR in a table in the add-
itional file. The mean and median treatment rates for
each treatment are very close, suggesting that even if
there are HRRs with outlier treatment rates, these rates
are balanced above and below the median HRR.
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Table 1 Mean treatment rates for recommended courses of care










resection w/12+ nodesa chemotherapyb radiation therapyc postoperative
chemotherapyd
no treatmente any treatmentf resectiong
Mean of TX 48 %(2760/5809) 54 %(1089/2009) 61 %(407/668) 48 %(248/518) 21 %(1119/5220) 88 %(5240/5978) 41 %(275/673)
Median Lubbock 48 %(77/161) Austin 56 %(51/91) Wichita Falls 60 %(6/10) Austin 54 %(19/35) Houston 21 %(223/1081) McAllen 89 %(48/54) Beaumont 40 %(8/20)
95 % CI 41 % to 50 % 95 % CI 53 % to 60 % 95 % CI 58 % to 69 % 95 % CI 42 % to 59 % 95 % CI 18 % to 26 % 95 % CI 85 % to 91 % 95 % CI 36 % to 48 %
Minimum Victoria 27 %(24/90) Beaumont 44 %(21/48) Temple 40 %(2/5) El Paso 0 %(0/7) Harlingen 8 %(5/60) Amarillo 68 %(145/212) San Antonio 22 %(15/67)
Maximum Wichita Falls 59 % (51/86) Longview 71 %(17/24) Bryan 100 %(2/2) Victoria 75 %(6/8) Amarillo 36 %(53/149) Odessa 96 %(48/50) San Angelo 75 %(3/4)
n = total number of treated patient in each HRR, N = total number of patient in each HRR
ahad colorectal resection with at least 12 nodes removed within 6 months of diagnosis
bhad chemotherapy within 4 months of diagnosis
chad radiation therapy within 6 months of diagnosis
dhad rectal resection within 6 months of diagnosis and postoperative chemotherapy
edid not have any of following treatments within 12 months of diagnosis: external beam radiation therapy, brachytherapy, prostatectomy, cryosurgery, or androgen deprivation therapy(orchiectomy or medical)
fhad any of following treatments within 12 months of diagnosis: external beam radiation therapy, brachytherapy, prostatectomy, cryosurgery, or androgen deprivation therapy(orchiectomy or medical)















Similar to previous research, mean rates of recom-
mended care for colorectal cancer patients in Texas are
relatively low [28]. The rate of removal of 12+ lymph
nodes during colon cancer resection is lowest in the HRR
of Victoria (27 %) and highest in Wichita Falls (59 %).
Differences between HRRs with the lowest and highest
rates of chemotherapy for regional colon cancer are simi-
larly wide (44 % for Beaumont, versus 71 % for Longview).
We do not have sufficient numbers of patients with rectal
cancer in all HRRs across Texas to draw conclusions
regarding this patient group.
Similar to past research, few older men with a favor-
able prognosis for prostate cancer are managed with
observation and instead receive cancer-directed treat-
ment. Most men with unfavorable prostate cancer re-
ceive cancer-directed treatment such as prostatectomy
or external beam radiation. Even so, treatment rates for
prostate cancer patients differ markedly across HRRs.
Amarillo has the highest rate of recommended treat-
ment for patients with favorable risk (36 %), but the
lowest rate of recommended treatment for patients
with unfavorable risk profiles (68 %). Harlingen has the
lowest rate of appropriate care for prostate cancer pa-
tients with favorable risk (8 %), and Odessa has the
highest rate of treatment for patients with unfavorable
risk (96 %).
The mean rate of resection for pancreatic cancer pa-
tients with locoregional disease is only 41 %, similar to
findings from past research [15]. San Antonio has the
lowest rate of surgical resection (22 %), while San
Angelo has the highest rate (75 %). Given that the total
number of patients diagnosed with resectable logoregional
pancreatic cancer during the sample period is relatively
low (673), and the numbers of patients in the sample
with regional rectal cancer is also small (668), we test
for significant differences across regions of Texas using
regression analysis.
Table 2 contains results of logistic regressions where
we test for differences in the probability of receiving
recommended treatment across HRRs, without adjust-
ment for other patient factors. We find 8 out of 22
HRRs in Texas have rates of lymph node removal with
colon cancer surgery which are significantly different
from the median region of Lubbock. The regressions re-
veal no significant differences in rates of chemotherapy for
patients with regional colon cancer. We also find no sig-
nificant difference across HRRs in either recommended
therapies for rectal cancer patients.
The regressions indicate that 3 HRRs have odds ra-
tios of recommended care for favorable prostate cancer
patients which are lower than the median HRR of
Houston, where 21 % of patients are delivered cancer-
directed treatment despite recommendations not to do
so. Among prostate cancer patients with unfavorable risk
profiles, we found only one HRR with a treatment rate
that was significantly different from the median HRR of
McAllen. We found no statistically significant differences
in unadjusted resection rates for pancreatic cancer pa-
tients across HRRs.
Table 3 reports results of logistic regressions testing
for significant differences in treatment rates across
HRRs, adjusted for patient characteristics and local spe-
cialist supply. These odds ratios are also graphed in
Fig. 1, with statistically significant odds ratios in red
and statistically insignificant odds ratios in yellow.
Descriptive statistics on the means for each of the
explanatory variables in the regressions are listed in a
table in the additional file. The number of HRRs with
rates of removal and examination of lymph nodes for
resected colon cancer patients rises to 13, versus 8 in
the unadjusted results. A total of 7 HRRs have removal
rates which are significantly lower than the median
HRR of Lubbock. In McAllen, the lowest outlier, the
odds ratio for removal of 12+ lymph nodes for colon
resection patients is 0.5 (p < 0.01). The highest outlier,
Wichita Falls, has an odds ratio of removal of 12+
lymph nodes equal to 2.3 (p < =0.01).
Unlike the unadjusted results, five HRRs have odds
ratios of chemotherapy for patients with regional colon
cancer which are significantly different (and higher)
compared to the median HRR of Austin. McAllen is the
highest outlier, with an odds ratio of chemotherapy
equal to 3.0 (p < 0.00).
Among rectal cancer patients, there were no signifi-
cant differences in treatment rates across HRRs in the
unadjusted results. In the adjusted results, there were
four HRRs with significantly different treatment rates
relative to the median HRR. In El Paso, the odds ratio of
radiation therapy for patients with regional rectal cancer
was 3.3 (p = 0.04) relative to Wichita Falls. Abilene, San
Angelo and Victoria all had significantly higher odds
ratios of postoperative chemotherapy for patients with
regional rectal cancer (7.7, p < 0.01; 4.3, p < 0.01; and 6.6,
p < 0.01 respectively).
The adjusted regressions show nine HRRs have treat-
ment rates for prostate cancer patients with favorable
risk to be significantly different from the median (as op-
posed to only 3 HRRs in the unadjusted results). The
lowest outlier, Harlingen, has an odds ratio equal to 0.3
(p = 0.04) relative to the median HRR of Houston. The
highest outlier is Amarillo, with an odds ratio equal to
2.4 (p < 0.01). Among prostate cancer patients with
unfavorable risk, only two HRRs had treatment rates
that were significantly different from the median rate in
McAllen. Amarillo is again the lowest outlier, with an
odds ratio of 0.20 (p < 0.01). Unlike the unadjusted
comparisons, two HRRs had rates of pancreatic resec-
tion that were significantly lower than the median HRR
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(Beaumont) in the adjusted regressions. El Paso had an
odds ratio of 0. (p = 0.0), and San Antonio had an odds
ratio of 0.3 (p < 0.01).
In the adjusted regressions, the patient characteristics
gender, age category, race/ethnic origin, rural/urban lo-
cation, Charlson score, tumor size, year of diagnosis,
and median income are each significantly associated
with the probability of receiving treatment for at least
one recommended cancer treatment type. Older age,
being black, having two or more Charlson comorbidities,
and living in a lower income area all reduce the likelihood
of receiving treatment for at least three recommended
therapies. The year of diagnosis affects the likelihood of
treatment in 4 of the 7 treatment types, but not in a sys-
tematic manner. The presence of a teaching hospital in an
HRR does not appear to systematically influence treat-
ment rates. Dallas and Houston have the highest number
of teaching hospitals, but neither area has significantly
higher or lower treatment rates than the median HRR. In
contrast, Amarillo, which houses a teaching hospital for
Texas Tech, reports a significantly higher rate of colon
cancer resections with 12 or more lymph nodes removed;
and a significantly lower rate of prostate cancer patients
with an unfavorable prognosis receiving treatment. We
could not formally test for the association between the
number of teaching hospitals and treatment rates in this
sample. Only 7 of 22 HRRs had 1 or more teaching hospi-
tals, and 4 had only one present. Therefore there was not
enough variation in the number of teaching hospitals to
overcome multicollinearity issues.
The local supply of specialists in the area where each pa-
tient is treated is not an important determinant of whether
a patient receives recommended care. Colorectal cancer
patients who were resected in HSAs with 10 or more
surgeons per cancer patient were more likely to have 12+
lymph nodes removed with surgery (OR = 1.61, p < 0.001),





























Treatment Rate 48 % 54 % 61 % 48 % 21 % 88 % 41 %
Hospital referral region
Abilene 0.6 (0.03) 1.3 0.7 1.7 1.4 0.9 2.3
Amarillo 1.5 1.3 1.7 1.3 2.1 0.3 (<0.01) 1.7
Austin 1.5 (0.05) 1 0.8 1 0.5 (<0.01) 2.3 0.9
Beaumont 0.6 (0.01) 0.6 1.7 1.7 1.8 (<0.01) 0.7 1
Bryan 1.5 1.4 (omitted) (omitted) 1.2 1.3 0.5
Corpus Christi 0.6 (0.01) 0.7 1.9 1.2 1.2 1.4 0.6
Dallas 1 0.9 1.2 0.6 0.7 (<0.01) 1.3 1.3
El Paso 1.2 0.7 2.2 (omitted) 1.4 0.7 0.8
Fort Worth 1.2 0.9 0.8 1.1 0.9 0.8 1.2
Harlingen 0.6 (0.01) 1.1 0.7 0.8 0.4 (0.03) 3 0.6
Houston 1.1 0.9 0.9 0.6 1 0.9 1.1
Longview 1.2 1.9 1 0.5 0.9 1.4 0.9
Lubbock 1 1.6 0.8 1.2 1 1.1 1.5
McAllen 0.5 (<0.01) 1.6 1.1 1 1.6 1 1.3
Odessa 1.2 0.8 1.5 1.5 0.8 3 3
San Angelo 0.8 0.6 2 2.1 2 (<0.01) 0.6 4.5
San Antonio 1.2 0.8 0.8 0.6 1.7 (<0.01) 0.4 0.4
Temple 0.6 1.2 0.4 1.7 1.5 0.7 2
Tyler 1.2 1.2 1.3 1 1.5 (0.01) 1 1
Victoria 0.4 (<0.01) 1.4 1 2.5 0.5 1.1 0.6
Waco 0.6 (0.03) 0.8 1 1 0.8 1 0.9
Wichita Falls 1.6 1.2 1 0.6 0.4 1.8 0.8
Sample Size 5809 2009 668 518 5220 5978 673
Numbers in parentheses are p-values. Bolded coefficients have p-values less than 0.05. For ease of reading, p-values greater than 0.05 are not reported
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but such effects were not precisely estimated for any of
the other recommended cancer therapies. Neither the
number of radiation oncologists or urologists per can-
cer patient were significant predictors of the probability
of treatment for patients with a favorable prognosis for
prostate cancer treatment. Therefore, the theory supply
sensitive care does not appear to explain the tendency
to practice aggressive treatment for this population
instead of active surveillance.
Discussion
Previous studies have already identified low rates of
appropriate treatment in the U.S. for the cancers that we
consider [15, 16, 28, 37]. For example, a previous analysis
of SEER data found that only 37 % of 116,995 colorectal
cancer patients received adequate lymph node evaluation
[38]. This paper tests for regional variation in treatment
rates around these low absolute levels of appropriate care.
We also examine multiple cancer types simultaneously, to
determine whether there are regions which tend to be
more or less aggressive in treatment.
We find at least some significant difference in treatment
rates for 7 recommended therapies across regions of
Texas. The variation in treatment rates are particularly
notable for colon cancer and for prostate cancer patients
with favorable risk. Of 22 HRRs in Texas, the likelihood
that 12+ lymph nodes are removed for resected colon
cancer patients is significantly higher or lower for 13
HRRs relative to the median HRR.
These differences are not due to variation in patient
characteristics across regions. When we adjust for pa-
tient characteristics, the disparities are actually wider.
Among prostate cancer patients with a favorable risk
profile, 9 HRRs have treatment rates significantly
higher or lower than the median region. The differences
also do not appear to be associated with population





























Treatment Rate 48 % 54 % 61 % 48 % 21 % 88 % 41 %
Hospital referral region
Abilene 1.1 1.7 0.5 7.7 (<0.01) 1.6 (0.03) 0.71 1.9
Amarillo 1.7 (0.02) 1.5 1.7 1 2.4 (<0.01) 0.2 (<0.01) 2.2
Austin 1.5 1 0.8 1 0.6 (0.01) 1.7 0.7
Beaumont 0.6 (0.05) 0.8 1.9 2.6 1.9 0.6 1
Bryan 1.7 (0.02) 1.9 (0.03) (omitted) (omitted) 1.4 1.1 0.5
Corpus Christi 0.6 (<0.01) 1 2.5 0.8 1.2 1.2 1.3
Dallas 0.9 0.9 1.3 0.8 0.8 1 1
El Paso 1.2 0.9 3.3 (0.04) (omitted) 1.1 0.7 0.4 (0.02)
Fort Worth 1.4 (0.01) 1 1 1.6 1.1 0.5 1.2
Harlingen 0.6 (<0.01) 1.8 (0.03) 1.2 0.7 0.3 (0.04) 2.7 0.8
Houston 1.1 1 1 0.7 1 0.8 1
Longview 1.4 2 1.2 1.3 0.9 1.2 0.5
Lubbock 1 1.9 (<0.01) 0.9 1 1 1 1.2
McAllen 0.5 (<0.01) 3.0 (<0.01) 2 0.9 1.3 1 0.9
Odessa 1.3 (0.05) 1 2.2 1.6 0.8 2.6 2.6
San Angelo 0.8 0.8 1.5 4.3 (<0.01) 2.1 (<0.01) 0.4 4.5
San Antonio 1.2 1 0.9 0.6 1.8 (<0.01) 0.3 (0.01) 0.3 (<0.01)
Temple 0.6 1.2 0.7 3 1.6 (0.02) 0.6 1.1
Tyler 1.3 1.2 1.7 1.4 1.7 0.9 1.4
Victoria 0.5 (<0.01) 2.0 (<0.01) 1.1 6.57 (<0.01) 0.6 (<0.01) 1 0.7
Waco 0.7 (0.04) 0.9 1 1.2 0.8 0.8 0.6
Wichita Falls 2.3 (<0.01) 1.5 1 1.9 0.5 (0.01) 1.5 1.1
Sample Size 5809 2009 668 518 5220 5978 673
Numbers in parentheses are p-values. Bolded coefficients have p-values less than 0.05. For ease of reading, p-values greater than 0.05 are not reported
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Fig. 1 Adjusted Odds of Receiving Recommended Treatment by HRR
Ho et al. BMC Health Services Research  (2016) 16:262 Page 8 of 11
size. Most of the smaller HRRs [39] have significantly
higher or lower rates of treatment relative to the me-
dian for at least one recommended cancer treatment.
However, San Antonio is the third largest HRR in Texas
in terms of Medicare beneficiaries, and it has signifi-
cantly different treatment rates for both prostate cancer
treatments and pancreatic resection. In addition, Fort
Worth and Austin, the fourth and fifth largest HRRs,
have significantly higher rates of lymph node resection
for patients with colorectal cancer.
Some past literature concludes that certain regions
provide more aggressive health care than others [11, 40].
However, these studies examined aggregate measures of
health care utilization, such as the number of medical
specialist visits or the percent of hospital patients admit-
ted to an intensive care unit in a region. In contrast, we
find that regions can provide above or below median
rates of treatment when one looks at multiple different
cancer types and recommended treatments. No HRR
performs systematically better or worse in treatment
levels for all 7 recommended courses of cancer care that
we studied. For each individual HRR, one can find odds
ratios of receiving recommended treatment that are
greater or less than one across the 7 courses of care that
we examine. The HRR with the median rate of treatment
is different for each of the 7 therapies as well.
Multiple studies associate the availability of primary
care physicians and the role they play in screening with
improved cancer survival [19–26]. One recent study
found an association between increased specialist supply
and lower cancer mortality across counties in the U.S.
[25]. However, we found only one instance out of several
(availability of surgeons for removal of lymph nodes for
colorectal cancer resection) in which the availability of
specialists is associated with receipt of appropriate care.
With the large increase in insured persons following the
implementation of the Affordable Care Act, some policy
makers have been concerned that greater demand for
health care will lead to a physician shortage. Patients
may face difficulty obtaining screening and referrals
from primary care physicians, but increased demand for
specialist care may not be the most important factor in
determining delivery of appropriate treatment for cancer
patients. Insurance coverage is also an important deter-
minant for whether a patient receives treatment, but our
analyses was based on patients covered by Medicare.
It may be that the underlying factors influencing dif-
fering rates of treatment across regions vary by cancer
type. Different specialists are responsible for treating
the three major cancers we consider, and their practice
styles and referral patterns may be an important deter-
minant of variations in care. These differences do not
appear to be influenced by proximity to teaching hospi-
tals, because treatment rates are either higher or lower
than the median in each HRR, regardless of the pres-
ence of teaching hospitals in each region.
Our study has certain caveats. The mean rate of treat-
ment for colorectal and pancreatic cancer patients is so
low, that there may be “more room” for variation
among HRRs than one might observe elsewhere in the
U.S. However, the rate of pancreatic resection of 34 %
measured in our study is comparable to the 28.6 % rate
of surgical resection identified in a previous nationwide
study [15]. The absence of regional variation in recom-
mended treatments for rectal cancer may be due to the
relatively small number of patients with this cancer in
our sample. We also lack information that would allow
us to determine how much low levels of treatment are
attributable to physician actions versus patient refusal
to accept treatment, or financial barriers to receiving
care.
For the three of the seven recommended treatments,
there were only one or two regions out of 22 that had
significantly different adjusted treatment rates from the
median HRR. It is possible that one or two regions
appeared significantly different for these treatments due
to random chance, given that so many regions were
simultaneously compared to each other. Unfortunately,
we do not have an appropriate method for adjusting the
p-value below 0.05 to account for these multiple com-
parisons. A Bonferroni correction can be applied to ad-
just p-values when one multiple independent tests of the
same hypothesis. However, the regional comparisons in
this analysis are correlated rather than independent [41].
Because we are analyzing Medicare claims data, we are
missing information on patients under age 65 in the U.S.
Physicians are more likely to treat patients under age 65
more aggressively, [42] although regional variation in the
propensity of cancer patients to receive treatment may
persist for this younger population. The majority of pa-
tients under age 65 have privately purchased health insur-
ance. However, Texas has the highest rate of uninsured
adults ages 18 to 64 in the U.S., with as many as 25 %
uninsured during the study period [43]. Lack of health in-
surance has been associated with diagnosis at a later stage
and shorter survival time [44]. Because U.S. residents are
covered by multiple private health insurance companies, it
is prohibitively expensive to collect data for the under age
65 population that is as comprehensive as the TCR-
Medicare data used in this study.
Conclusion
Our results suggest that regions in Texas differ widely
in adherence to recommended treatment for seven dif-
ferent cancer interventions. These differences are not due
to the availability of specialists or the presence of teaching
hospitals. The absence of consistent explanators suggests
that variations like these are likely to occur elsewhere
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nationwide. Regions with high rates of success in one
treating one type of cancer cannot be assumed to excel in
other areas. Moreover, previous studies that classify local
areas as high-use or low-use may mask important differ-
ences within areas with respect to adherence to treatment
guidelines.
Identifying the underlying causes of regional differences
in adherence to guidelines will require more in-depth
studies than have so far been conducted. A comprehensive
review of the literature on barriers to guideline adherence
identified multiple barriers to adherence. However, most
studies only examined one or two potential causes [45].
The review divided studies into barriers due to physician
knowledge, attitudes, and behavior. Examples that may
be particularly relevant to cancer treatment include
lack of familiarity with guidelines, lack of agreement in
the benefits of treatment versus the risks, inertia of
previous practice, and patient-related barriers. Future
studies of adherence to recommended treatment should
be designed to examine all of these possibilities.
Other researchers suggest that more emphasis should
be placed on Continuing Medical Education programming
that disseminates recent guideline changes to physicians.
With the dissemination and improvement in electronic
health records, more quality monitoring at the physician
level could help to raise overall levels of adherence for all
HRRs [46]. A particularly promising model for Texas may
be Michigan’s Oncology Quality Consortium [47]. This
group represents a consortium of 40 physician organiza-
tions from across Michigan who received funding from
Blue Cross Blue Shield of Michigan to collect patient data
to track their quality of care. The information has allowed
the organization to design quality and process improve-
ment interventions. Physicians may have more success
obtaining financial support from private insurers to im-
prove cancer care at the state level, because insurers can
attract more customers if they can demonstrate higher
quality care in their network of providers. Adherence to
guidelines may also lower the costs of cancer care for in-
surers [48, 49].
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